Podcast

Raymond Douglas, MD, PhD: Treatment of Thyroid Eye Disease in 2020

Raymond Douglas, MD, PhD, discusses trends in treatment of thyroid eye disease and how the approval of teprotumumab has impacted the prospect of treating the condition.

This episode of the Endocrine Outlook features a conversation with Raymond Douglas, MD, PhD, of Cedars-Sinai Medical Center. In the interview, Douglas discusses and offers perspective on a recent study he led examining trends in treatment of active, moderate-to-severe thyroid eye disease in the United States.

With data collection ending in 2018, the study does not reflect changes in treatment that have come after the approval of teprotumumab (Tepezza) but Douglas asserts it offers an accurate overview of therapies used to control symptoms from the disease. Later in the interview, Douglas reflects on how the approval of teprotumumab has impacted treatment algorithms and how the ongoing pandemic has impacted the lives of patients with thyroid eye disease.

This study, “Trends in treatment of active, moderate-to-severe thyroid eye disease in the United States,” was published in the Journal of the Endocrine Society.

Related Videos
Diabetes Dialogue: Diabetes Tech Updates from November 2024 | Image Credit: HCPLive
Diabetes Dialogue: Tirzepatide’s Long-Term Obesity Data | Image Credit: HCPLive
Diabetes Dialogue: Latest Updates on Semaglutide Shortage, Data | Image Credit: HCPLive
Richard Pratley, MD | Credit: Advent Health Diabetes Institute
Rahul Aggarwal, MD | Credit: LinkedIn
Brendon Neuen, MBBS, PhD | Credit: X.com
HCPLive Five at ADA 2024 | Image Credit: HCPLive
Ralph DeFronzo, MD | Credit: UT San Antonio
Timothy Garvey, MD | Credit: University of Alabama at Birmingham
Atul Malhotra, MD | Credit: Kyle Dykes; UC San Diego Health
© 2024 MJH Life Sciences

All rights reserved.